$QURE

Kapusta Matthew C sold $952K of QURE

Kapusta Matthew C (CEO, Managing Director) sold 21,082 shares of uniQure N.V. (QURE) at an average of $45.16 ($44.43–$45.89, $0.95M total) across 3 trades on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kapusta Matthew C
Published Jul 7, 2026, 8:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest disclosed fact is the CEO’s open-market sale amount, share count, and the fact it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Provides a fresh datapoint on insider activity, but with 10b5-1 context it is unlikely to drive a major repricing alone.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent fundamental catalysts (earnings, trial updates) not present in this filing.

Relevance 4/10Novelty 4/10Timing: Filed after-hours on 2026-07-07; reflects sales executed on 2026-07-02.

Background

The article is a SEC Form 4 insider transaction report for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure CEO Matthew C Kapusta sold $952,051 of QURE shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 open-market sale with a stated 10b5-1 plan, which typically reduces signaling value versus discretionary selling.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may be largely mechanical and not a bearish signal.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • Kapusta Matthew C

    CEO, Managing Director; reported open-market sale of QURE shares under a 10b5-1 plan.

Related articles

$QUREMed

uniQure (QURE) Q2 2026 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.

$QUREMed

Gene therapy shows benefits in all participants in Fabry clinical trial

uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.

$QUREMedAI 8/10

Why is uniQure stock surging today? By Investing.com

uniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.

$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.

$QUREMed

uniQure N.V. (QURE): Results of Operations and Financial Condition

uniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline fo

$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure N.V. (Nasdaq: QURE) said it closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 each, including 741,758 shares from full exercise of the underwriters’ option. Gross proceeds were about $259 million before underwriting fees and expenses. Net proceeds will fund AMT-130 commercialization readiness, a confirmatory study, other clinical programs, business development, and general corporate purposes.